RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - INTERAZIONE TRA VIRUS DI EPSTEIN-BARR E CELLULA OSPITE
• 2 - Meccanismi molecolari di carcinogenesi: validazione di nuovi bersagli per la diagnosi e la terapia
• 3 - Patogenesi molecolare dei linfomi in funzione della terapia
• 4 - Un approccio biomolecolare per la patologia HHV8-associata e la sua possibile trasformazione neoplastica:
• 5 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 6 - Ruolo dell'FGFR2 e di altri cofattori nell'etiopatogenesi di tumori epiteliali.
• 7 - Sviluppo e progressione del carcinoma epatocellulare: meccanismi molecolari ed implicazioni terapeutiche
• 8 - BERSAGLI MOLECOLARI PER NUOVE TERAPIE ANTINEOPLASTICHE ATTRAVERSO LO STUDIO DI PROTEINE-SEGNALE CELLULARI E VIRALI E DI INIBITORI SPECIFICI
• 9 - IL CORONAVIRUS DEL CANE: ASPETTI MOLECOLARI E PATOGENETICI
• 10 - Inibizione della crescita neoplastica mediante manipolazione dell'equilibrio tra le vie di segnalazione JAK-STAT

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • MICROBIOLOGIA E MICROBIOLOGIA CLINICA
  • MALATTIE DEL SANGUE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Lazio

Bibliografia

Referenze:

Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, Mayer S, Takahashi S, Licht JD, Prive GG. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
Mol Cell. 2003 Dec;12(6):1551-64.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503-11

Altiok E, Minarovits J, Hu LF, Contreras-Brodin B, Klein G, Ernberg I. Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):905-9

Ambinder RF, Robertson KD, Tao Q. DNA methylation and the Epstein-Barr virus. Semin Cancer Biol. 1999 Oct;9(5):369-375.

Amini RM, Berglund M, Rosenquist R, Von Heideman A, Lagercrantz S, Thunberg U, Bergh J, Sundstrom C, Glimelius B, Enblad G. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma. 2002 Nov;43(11):2179-89.

Anastasiadou E, Boccellato F, Cirone M, Kis LL, Klein E, Frati L, Faggioni A, Trivedi P. Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virus. Leukemia. 2005 Oct;19(10):1854-1856.

Carbone A, Gaidano G, Gloghini A, Pastore C, Saglio G, Tirelli U, Dalla-Favera R, Falini B. BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression.
Am J Pathol. 1997 Jan;150(1):155-65.
Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6947-52.

Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997 Apr 25;276(5312):589-92

French SW, Malone CS, Shen RR, Renard M, Henson SE, Miner MD, Wall R, Teitell MA. Sp1 transactivation of the TCL1 oncogene. J Biol Chem. 2003 Jan 10;278(2):948-55.

Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1;84(5):1361-1392.]

Hoyer KK, French SW, Turner DE, Nguyen MT, Renard M, Malone CS, Knoetig S, Qi CF, Su TT, Cheroutre H, Wall R, Rawlings DJ, Morse HC 3rd, Teitell MA. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14392-7.

Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 2000 Jul 15;14(14):1810-23.


Huynh KD, Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene. 1998 Nov 12;17(19):2473-

Kelly, G., A. Bell and A. B. Rickinson. 2002. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med. 8:1098-1104.

Kiss, C., J. Nishikawa, K. Takada, P. Trivedi, G. Klein and L. Szekely. 2003. T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines. Proc Natl Acad Sci U S A. 100:4813-8

Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol. 1998 Nov;72(11):9150-6.

Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005 Apr;5(4):251-62

Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000 Aug;6(2):395-407

Masucci MG, Contreras-Salazar B, Ragnar E, Falk K, Minarovits J, Ernberg I, Klein G. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol. 1989 Jul;63(7):3135-41.

Niu H, Ye BH, Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 1998 Jul 1;12(13):1953-61.

Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003 Apr 15;101(8):2914-23

Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.
Nat Immunol. 2000 Dec;1(6):526-32.

Polack A., K. Hortnagel, A. Pajic, B. Christoph, B. Baier, M. Falk, J. Mautner, C. Geltinger, G. W. Bornkamm and B. Kempkes. 1996. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci U S A. 93:10411-6

Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987 Sep;6(9):2743-51.

Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.
Immunity. 2000 Aug;13(2):199-212.

Stage, M. S., S. P. Lee, T. Frisan, J. Mautner, S. Scholz, A. Pajic, A. B. Rickinson M. G. Masucci, A. Polack and G. W. Bornkamm GW. 2002. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A. 99:4550-4555

Teitell MA. The TCL1 family of oncoproteins: co-activators of transformation.
Nat Rev Cancer. 2005 Aug;5(8):640-8

Thorley-Lawson DA. EBV the prototypical human tumor virus--just how bad is it?
J Allergy Clin Immunol. 2005 Aug;116(2):251-61;

Trivedi P, Spinsanti P, Cuomo L, Volpe M, Takada K, Frati L, Faggioni A. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain. J Virol. 2001 May;75(10):4929-35.

Trivedi P, Takazawa K, Zompetta C, Cuomo L, Anastasiadou E, Carbone A, Uccini S, Belardelli F, Takada K, Frati L, Faggioni A. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood. 2004 Jan 1;103(1):313-6.

Wolniak KL, Shinall SM, Waldschmidt TJ. The germinal center response. Crit Rev Immunol. 2004;24(1):39-65

Wong CW, Privalsky ML. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. J Biol Chem. 1998 Oct 16;273(42):27695-702.

Ye BH, Rao PH, Chaganti RS, Dalla-Favera R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res. 1993 Jun 15;53(12):2732-5.

Ye BH, Cattoretti G, Shen Q, Zhang J, Hawe N, de Waard R, Leung C, Nouri-Shirazi M, Orazi A, Chaganti RS, Rothman P, Stall AM, Pandolfi PP, Dalla-Favera R. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.
Nat Genet. 1997 Jun;16(2):161-70.


Young LS, Rickinson AB. Related Epstein-Barr virus: 40 years on.
Nat Rev Cancer. 2004 Oct;4(10):757-68.

Zelenetz AD, Chen TT, Levy R. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. J Exp Med. 1991 Jan 1;173(1):197-207

Parole Chiave

VIRUS DI EPSTEIN-BARR, LINFOMI, CENTRO GERMINATIVO, LATENZA, LINFOMI B DIFFUSE A GRANDE CELLULE, ONCOGENI